Utilizing IP Street, you can search within technology classes to identify firms and patents anchored within a scope of inventions. Whether you are looking for inbound or outbound licensing opportunities, our search tools can help you Discover, Measure, Compare, Connect to, better business opportunities.
Although subtle, there is a keen difference between invention and innovation. Utility represents this distinct difference between innovation and invention. Albeit important, inventors generally spend their fortunes on their ideas whereas innovators create fortunes from their ideas. Our goal is to help you become more than an inventor. Since innovation is generally considered the actualization of an invention, and we claim as a promise to innovate continuously, are we hypocrites? If we don't listen to you and develop tools, reports, and lenses that have meaning to you, indeed we would be. Only you can decide that for yourself. However, our commitment to you is to continue innovating tools and services that help you rationalize IP asset class. While previous analytical tools focused on finding data, our tools are built to help you both find and then undertand what you found. Our data and technologies are only vehicles to help us deliver on our promise — we create actionable business intelligence from patent documents.
In the U.S., the inventor has a "first to invent" claim which is different from other patenting organizations throughout the world who generally utilize "first to file." Debate over this issue, and which model best influences economic development is ongoing. Some are concerned that a change in patent rights may harm the small startup and benefit the incumbents with deeper pockets. You can read more about this topic.
For us to be successful, we need to understand your needs and deliver technologies that meet your needs. This is the essence of co-creation or synergy. We both benefit from having an ongoing relationship. With this in mind, we want to emphasize our commitment to you, our customer. You are the reason we are in business. Lewis' original idea came from working with people like you — people with a desire to better understand how the IP landscape influences business strategy and decision making. our commitment to you. For us to be successful, we need to understand your needs and deliver technologies that meet your needs. This is the essence of co-creation or synergy. We both benefit from having an ongoing relationship. With this in mind, we want to emphasize our commitment to you, our customer. You are the reason we are in business. Lewis' original idea came from working with people like you — people with a desire to better understand how the IP landscape influences business strategy and decision making. Here at IP Street, we believe you belong on a pedestal. Rather than develop technologies and impose them upon you, we are interested in providing a different model. Listening to you, understanding what you need based on our subject matter expertise, and then providing tools that meet those needs. So far, we have heard that you want a simplification of complex patent documents. You want more than search results, you want visual results that have concrete, real-world significance. You want efficient patent search tools, better resources to patent duration and determining patent value. You want business intelligence from IP that is meaningful and actionable. Are we right? For many of you, based on what you have been telling us about what our product can do, we believe we are. However, we are still listening. So if you have further suggestions and wishes, please do not hesitate to contact us.
Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.
(1) Word.
